Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis

BACKGROUND: The best investigational drug to treat cystic fibrosis (CF) patients with the most common CF-causing mutation (F508del) is VX-809 (lumacaftor) which recently succeeded in Phase III clinical trial in combination with ivacaftor. This corrector rescues F508del-CFTR from its abnormal intrace...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EBioMedicine
Main Authors: Awatade, Nikhil T., Uliyakina, Inna, Farinha, Carlos M., Clarke, Luka A., Mendes, Karina, Solé, Amparo, Pastor, Juan, Ramos, Maria Margarida, Amaral, Margarida D.
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2014
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4484512/
https://ncbi.nlm.nih.gov/pubmed/26137539
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2014.12.005
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados